NAD+ and Vitamin B12

Overview

The NAD+ and vitamin B12 blend is a fixed-ratio research combination of two distinct cellular compounds: nicotinamide adenine dinucleotide (NAD+), a redox coenzyme present in every living cell, and vitamin B12 (cobalamin), an essential water-soluble vitamin. In the controlled-dose format stocked by research suppliers, a single vial contains 1,000 mg of NAD+ and 8 mg of vitamin B12.

Each component has its own established body of research. NAD+ is one of the most studied molecules in cellular biology, and vitamin B12 is a well-characterized essential nutrient with decades of clinical use as a deficiency treatment. The specific combination of the two at this fixed ratio, however, has not been evaluated as a single product in controlled clinical or preclinical studies. The pairing reflects a theoretical interest in supporting energy metabolism and methylation chemistry at the same time, rather than the result of a formal combination trial.

This profile summarizes the published research on each component separately and is provided strictly as educational reference material. The blend is sold for laboratory research use only and is not a medicine, supplement, or treatment.

Mechanism of Action

NAD+ and vitamin B12 act through entirely separate biochemical pathways. The blend combines two unrelated mechanisms rather than two parts of one system.

NAD+: redox coenzyme and enzyme substrate

NAD+ functions as an electron carrier in central energy metabolism. It accepts electrons during glycolysis, fatty acid oxidation, and the citric acid cycle, becoming NADH, which then donates those electrons to the mitochondrial electron transport chain to drive ATP synthesis. Beyond this redox role, NAD+ is consumed as a substrate by three families of enzymes: the sirtuins (NAD+-dependent deacylases involved in gene-expression regulation), the poly(ADP-ribose) polymerases or PARPs (involved in DNA-damage repair), and CD38. Because these enzymes consume NAD+, cellular NAD+ must be continuously regenerated and resynthesized through salvage and de novo pathways.

Vitamin B12: methylation and mitochondrial cofactor

Vitamin B12 serves as a cofactor for only two enzymes in human cells. As methylcobalamin it supports methionine synthase, which converts homocysteine to methionine and links B12 status to folate metabolism and one-carbon (methylation) chemistry. As adenosylcobalamin it supports methylmalonyl-CoA mutase, a mitochondrial enzyme in the pathway that processes certain fatty acids and amino acids. A deficiency of B12 disrupts both reactions, which underlies the megaloblastic anemia and neurological signs seen in clinical B12 deficiency.

The rationale for combining the two is that NAD+ relates to redox energy metabolism while B12 relates to methylation and a separate mitochondrial step. Whether co-administration produces any effect beyond that of the individual compounds has not been studied.

Research Summary

Research on NAD+ as an intravenously administered compound is limited and early-stage. A frequently cited pilot study (Grant et al., 2019, Frontiers in Aging Neuroscience) tracked plasma and urinary NAD+ and its metabolites during a six-hour intravenous infusion and reported that measurable changes in the circulating NAD+ metabolome did not appear until roughly two hours into the infusion. A 2023 systematic review in the American Journal of Physiology-Endocrinology and Metabolism examined NAD and its precursors across clinical conditions and concluded that human efficacy data remain limited and inconsistent. Commercial intravenous NAD+ is widely offered in wellness settings, but reviewers have repeatedly noted that marketing has outpaced the controlled evidence.

Vitamin B12, by contrast, is supported by a large and mature clinical literature. Injectable cyanocobalamin is an established, FDA-approved treatment for vitamin B12 deficiency and pernicious anemia, and the consequences of deficiency, including megaloblastic anemia, peripheral neuropathy, and cognitive changes, are well documented. Research interest centers on correcting deficiency; evidence that supplemental B12 benefits people who are already replete is weak.

No published study has evaluated the NAD+ and B12 combination as a single fixed-ratio product. Any description of what the blend does is therefore an inference drawn from the two separate literatures, not a finding about the blend itself.

Dosing in Published Research

For vitamin B12, the FDA-approved label for cyanocobalamin injection describes a regimen for diagnosed deficiency of 100 mcg given by intramuscular or deep subcutaneous injection daily for six to seven days, followed by tapering to every other day and then less frequent dosing, with lifelong monthly 100 mcg maintenance injections for pernicious anemia. These figures apply to the medically supervised treatment of a diagnosed deficiency.

For NAD+, there is no approved medicine and no labeled dose. The small number of human studies have used intravenous infusions administered over several hours in research or clinical settings; they were designed to characterize NAD+ metabolism rather than to establish a standard dose, and no controlled trial has defined an effective or safe NAD+ dose for general use.

Safety and Side Effects

The safety considerations for the blend are those of its two components.

NAD+

The most consistently reported issue with intravenous NAD+ is infusion-related discomfort. When infused too quickly, NAD+ has been associated with flushing, chest or abdominal tightness, nausea, lightheadedness, and muscle cramping; slowing the infusion rate generally reduces these effects. Reviewers attribute some adverse effects to supraphysiologic extracellular NAD+ concentrations, which can have pro-inflammatory activity. Because human safety data come from small studies, long-term safety has not been established.

Vitamin B12

Vitamin B12 has a strong safety record. It is water-soluble, has no established tolerable upper intake level, and excess is largely excreted in urine. Reported adverse effects are uncommon and include injection-site reactions, rare hypersensitivity reactions to cobalamin, and acneiform skin eruptions at high doses. A practical clinical caution is that high-dose B12 can correct the anemia of a combined B12-and-folate deficiency while the underlying neurological damage of B12 deficiency continues to progress; this is one reason deficiency is evaluated and treated under medical supervision.

The blend

Because the combination has not been formally studied, its interactions and combined safety profile are unknown. It is sold strictly for in-vitro laboratory research and is not intended for human or veterinary use.

Current Research Status

The two components sit at very different points on the regulatory map. Injectable cyanocobalamin (vitamin B12) is an FDA-approved prescription medicine for the treatment of B12 deficiency and pernicious anemia. NAD+ itself is not an approved drug; it is sold as a research compound and offered through wellness clinics as an intravenous infusion outside of any approved indication, and the human efficacy evidence behind those uses remains limited.

The fixed NAD+ and B12 blend is not an approved product of any kind. It has not been the subject of a clinical trial as a combination, and it is marketed for laboratory and research use only. It should be treated as an experimental research material rather than a therapy, and the separate, better-established literature for each component is the appropriate source for factual information.

Frequently Asked Questions